Overview
Activates GLP-1 receptors on hepatocytes, reducing lipogenesis and increasing fatty acid oxidation.
Proposed mechanism
Semaglutide reduces liver fat by suppressing appetite, improving insulin sensitivity, and directly reducing de novo lipogenesis in hepatocytes.
What the evidence supports
Human data exists but the trials are small, short-term, or not yet replicated.
Graded Human-limited
Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
Semaglutide in NASH
· DOI:10.1056/NEJMoa2031482 · 2021
- [2]
Semaglutide in NASH (2021)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.